Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1992-4-22
|
pubmed:abstractText |
The effects exerted by oxiracetam on the disruption of performance induced by scopolamine in the radial arm maze were investigated in overtrained rats. Scopolamine induced a dose-related decrease in the efficiency of responding and an increase of running time. The effect of the SC injection of 0.2 mg/kg scopolamine on the efficiency of responding was antagonized by the IP administration of 30 mg/kg oxiracetam, while the effect on running time induced by the same dose of scopolamine was not. Physostigmine (0.3 mg/kg SC) antagonized both effects of 0.2 mg/kg scopolamine. Methylscopolamine, at the dose of 0.2 mg/kg SC, was devoid of any effect on both parameters. Increasing the dose of methylscopolamine to 0.63 mg/kg did cause serious peripheral effects which eventually prevented some animals from completing the task. Similar peripheral effects were observed after administration of 0.63 mg/kg scopolamine. The effects of this dose of scopolamine on efficiency and running time were not antagonized by pretreatment with 100 mg/kg oxiracetam. Oxiracetam alone (30 or 100 mg/kg IP) did not modify the performance of previously trained rats. The present results suggest that oxiracetam selectively restores cholinergic mechanisms which are involved in learning and memory.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/N-Methylscopolamine,
http://linkedlifedata.com/resource/pubmed/chemical/Parasympatholytics,
http://linkedlifedata.com/resource/pubmed/chemical/Physostigmine,
http://linkedlifedata.com/resource/pubmed/chemical/Psychotropic Drugs,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrrolidines,
http://linkedlifedata.com/resource/pubmed/chemical/Scopolamine Derivatives,
http://linkedlifedata.com/resource/pubmed/chemical/Scopolamine Hydrobromide,
http://linkedlifedata.com/resource/pubmed/chemical/oxiracetam
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0033-3158
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
106
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
175-8
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1549645-Animals,
pubmed-meshheading:1549645-Dose-Response Relationship, Drug,
pubmed-meshheading:1549645-Male,
pubmed-meshheading:1549645-Memory,
pubmed-meshheading:1549645-Motor Activity,
pubmed-meshheading:1549645-N-Methylscopolamine,
pubmed-meshheading:1549645-Parasympathetic Nervous System,
pubmed-meshheading:1549645-Parasympatholytics,
pubmed-meshheading:1549645-Physostigmine,
pubmed-meshheading:1549645-Psychotropic Drugs,
pubmed-meshheading:1549645-Pyrrolidines,
pubmed-meshheading:1549645-Rats,
pubmed-meshheading:1549645-Rats, Inbred Strains,
pubmed-meshheading:1549645-Scopolamine Derivatives,
pubmed-meshheading:1549645-Scopolamine Hydrobromide
|
pubmed:year |
1992
|
pubmed:articleTitle |
Oxiracetam antagonizes the disruptive effects of scopolamine on memory in the radial maze.
|
pubmed:affiliation |
ISF Laboratories for Biomedical Research, Milano, Italy.
|
pubmed:publicationType |
Journal Article
|